Gastrointestinal Conditions News

Carbapenem-resistant Enterobacteriaceae infections among children in Italy with immunosuppression and oncologic diseases were associated with significant morbidity and mortality, according to study findings.

A mixture of the probiotic Lactobacillus GG, vitamins B and C, and zinc, appeared to prevent nosocomial infections in children in an Italian randomized controlled trial.

Swedish children born in the spring, summer and autumn have an increased risk for developing celiac disease in childhood compared with those born in the winter, especially if they were born in the southern region of the country, according to the results of a prospective cohort study.

Nearly two-thirds of infants born in New York City with reportable bacterial infections during a 9-year period had enteric infections, according to recent study data.

Takeda Pharmaceuticals announced the FDA has approved Dexilant for patients aged between 12 and 17 years with GERD. The medication has been approved for adults since 2009.

Breast-feeding could significantly reduce the risk for diarrhea and feeding at the breast instead of from a bottle or formula may reduce otitis media infections in infants, according to recent survey results published in The Journal of Pediatrics.

Long-term use of swallowed Flonase safely maintained endoscopic and clinical improvements and reductions in esophageal eosinophils among children with eosinophilic esophagitis, according to the results of an open-label, prospective, single-center study.

Early life antibiotic exposure, delivery by cesarean section and formula feeding were associated with a disrupted development of the gut microbiome and reduced microbial diversity in infants, according to study results published in Science Translational Medicine.

Swedish male adolescents who were overweight had an increased risk for developing severe liver disease — such as cirrhosis — later in life, according to results of a population-based study.

The FDA has granted breakthrough therapy designation to two investigational drugs for eosinophilic esophagitis and progressive familial intrahepatic cholestasis type 2, respectively, the manufacturer announced.